CDK9 and acute myeloid leukemia: Drug sensitivity in AML cell lines showed that high ME1 expression was correlated with resistance to histone deacetylase inhibitors (HDACi) and to ruxolitinib (JAK1/2 inhibitor), while being sensitive to CDK9_5038, a CDK9 inhibitor, and ERK_6604, an ERK1/2 inhibitor (Supplementary Figure S4A).